Bisulfite intolerance manifest as bronchospasm following topical dipivefrin hydrochloride therapy for glaucoma.
D000328:Adult; D001249:Asthma / Q000139:chemically induced*; D004342:Drug Hypersensitivity / Q000150:complications*; D004837:Epinephrine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D010592:Pharmaceutic Aids / Q000009:adverse effects*; D011310:Preservatives, Pharmaceutical / Q000009:adverse effects*; D013447:Sulfites / Q000009:adverse effects*
D010592:Pharmaceutic Aids; D011310:Preservatives, Pharmaceutical; D013447:Sulfites; C005200:sodium metabisulfite; C015173:dipivefrin; D004837:Epinephrine